Compare MSLE & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSLE | CVRX |
|---|---|---|
| Founded | N/A | 2000 |
| Country | Canada | United States |
| Employees | 17 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 237.1M |
| IPO Year | N/A | 2021 |
| Metric | MSLE | CVRX |
|---|---|---|
| Price | $8.16 | $7.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.50 |
| AVG Volume (30 Days) | 91.2K | ★ 233.0K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | $16.65 |
| Revenue Next Year | N/A | $18.41 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $5.50 | $4.37 |
| 52 Week High | $13.39 | $11.30 |
| Indicator | MSLE | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 60.97 | 42.40 |
| Support Level | $6.67 | $6.71 |
| Resistance Level | $11.98 | $8.93 |
| Average True Range (ATR) | 0.73 | 0.71 |
| MACD | 0.41 | -0.20 |
| Stochastic Oscillator | 98.79 | 26.53 |
Satellos Bioscience Inc is a regenerative medicine company a biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.